Quantcast

Latest N30 Pharma Stories

2011-03-02 05:00:00

BOULDER, Colo., March 2, 2011 /PRNewswire/ -- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR), and the lack of apparent mechanism-based toxicities. GSNOR is a critical enzyme in the endogenous nitric oxide pathway, and its activity is thought...

2010-09-08 05:00:00

BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory...

2010-08-02 07:00:00

BOULDER, Colo., Aug. 2 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD). N30 Pharma will now begin a first-in-man, Phase 1, dose...

2010-05-11 07:00:00

BOULDER, Colo., May 11 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of a new class of proprietary therapeutics that conserve endogenous, bioactive nitric oxide, announced today that it has completed a $10 million financing and expanded its Board of Directors. Joining the Company's Board of Directors will be Dr. Howard Furst of Deerfield Management. "I am pleased with this successful financing. It will provide resources to move our...

2009-04-06 10:18:00

BOULDER, Colo., April 6 /PRNewswire/ -- N30 Pharma today announced the formation of its Scientific Advisory Board, or SAB. The purpose of the SAB is to assist the company in the design and execution of its discovery and development programs across cardiopulmonary medicine and Nitric Oxide (NO) and redox biology. Dr. Joseph Loscalzo, Chairman of the Department of Medicine at Brigham and Women's Hospital and Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School,...

2009-03-23 07:00:00

BOULDER, Colo., March 23 /PRNewswire/ -- N30 Pharma (N30) today announced that Joseph Loscalzo, M.D., PhD., has joined the Board of Directors of the Company. Dr. Loscalzo currently serves as Hersey Professor of the Theory and Practice of Medicine at Harvard, Physician-in-Chief at Brigham and Women's Hospital, Editor-in-Chief of Circulation, and has recently joined the senior editorial Board of Harrison's Principles of Internal Medicine. Dr. Loscalzo has longstanding research interests in...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related